Drug profile · INN
alseroxylon
RAUWILOID
alseroxylon (RAUWILOID) is a adrenergic receptor alpha antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — alseroxylon
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 4
- Programs
- 8
- Data quality
- 0.84
Quick answer
alseroxylon (RAUWILOID) is a adrenergic receptor alpha antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Adrenergic receptor alpha antagonist
Primary target: Adrenergic receptor alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 12246027
Compositions of bile acids and phenylbutyrate compounds
granted -
US 12186330
Compositions for improving cell viability and methods of use thereof
granted -
US 12138272
Methods and compositions for treating amyotrophic lateral sclerosis
granted -
US 11559533
Compositions of bile acids and phenylbutyrate compounds
granted
Frequently asked questions
What is alseroxylon?
alseroxylon (RAUWILOID) is a adrenergic receptor alpha antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for alseroxylon?
RAUWILOID is a marketed brand name for alseroxylon. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of alseroxylon?
alseroxylon has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.